Periodontitis-atherosclerosis syndrome: An expanded model of pathogenesis

Journal of Periodontal Research

Volumn 34, Issue 7, 1999, Pages 346-352

  Offenbacher, Steven ^a   Madianos, Phoebus N ^a   Champagne, Catherine M E ^a   Southerland, Janet H ^a   Raquette, David W ^a   Williams, Ray C ^a   Slade, Gary ^a   Beck, James D ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Periodontal medicine; Periodontitis

Indexed keywords

ARTERIOSCLEROSIS; ARTICLE; BACTERIAL INFECTION; FEMALE; HUMAN; INFLAMMATION; MALE; MICROBIOLOGY; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; PERIODONTITIS; RISK FACTOR; SYNDROME; THROMBOEMBOLISM;

ARTERIOSCLEROSIS; BACTERIAL INFECTIONS; FEMALE; HUMANS; INFLAMMATION; MALE; PATIENT CARE PLANNING; PERIODONTITIS; RISK FACTORS; SYNDROME; THROMBOEMBOLISM;

EID: 0033202582     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.1999.tb02264.x     Document Type: Article

References (23)

1. Beck JD, Garcia RG, Heiss G, Vokonas P, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996;67(suppl):1123-1137.
2. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol 1998;3: 51-61.
3. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999;25(suppl 3):32-40.
4. Deshpande RG, Khan MB, Genco CA. Invasion of aortic and heart endothelial cells by Porphyromonas gingivalis. Infect Immun 1998;66:5337-5343.
5. Madianos PN, Papapanou PN, Nannmark U, Dahlen G, Sandros J. Porphyromonas gingivalis FDC381 multiplies and persists within human oral epithelial cells in vitro. Infect Immun 1996;64:660-664.
6. Meyer DH, Lippmann JE, Fives-Taylor PM. Invasion of epithelial cells by Actinobacillus actinomycetemcomitans: a dynamic, multistep process. Infect Immun 1996;64: 2988-2997.
7. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996;1:821-878.
8. Haraszthy VI, Zambon JJ, Trevisan M, Shah R, Zeid M, Genco RJ. Identification of pathogens in atheromatous plaques. J Dent Res 1998;77(IADR abstr):666.
9. Chiu B. Multiple infections in carotid atherosclerotic plaques. In: International symposium in infection and atherosclerosis INSERM (abstr) 1998:95.
10. Libby P, Friedman GB, Salomon RN. Cytokines as modulators of cell proliferation in fibrotic diseases. Am Rev Respir Dis 1989;140:1114-1117.
11. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462-2478.
12. Imamura T, Potempa J, Pike RN, Travis J. Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis. Infect Immun 1995; 63:1999-2003.
13. Ebersole J, Machen R, Steffen M, Willmann D. Systemic acute-phase reactants, C-reactive protein and haptoglobin in adult periodontitis. Clin Exp Immunol 1997;107: 347-352.
14. Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. NEJM 1997;336:973-979.
15. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-428.
16. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998; 141:1-15.
17. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272: 20963-20966.
18. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998;93: 229-240.
19. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-252.
20. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996;51:1-9.
21. Morrow JD, Frei B, Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-1203.
22. Pratico D, Luliano L, Maurellio A et al. Localization of distinct F2-isoprostanes in human atheroscleroitic lesions. J Clin Invest 1997;100:2028-2034.
23. Pratico D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in Apo-E deficient mice. Nature Med 1999;4:1189-1192.